Clinical trials: Glomerulonephritis
IgA Nephropathy (IgAN), Membranous Nephropathy
Raman Spectroscopy Diagnosis of Kidney Diseases
This research plan, from January 2021 to December 2024, aims to collect serum and morning urine from patients diagnosed with IgA nephropathy, idiopathic membranous nephropathy, diabetic nephropathy, and focal segmental…
- Conditions
- IgA Nephropathy (IgAN), Membranous Nephropathy, Diabetic Nephropathy, Focal Segmental Glomerulosclerosis (FSGS)
- Trial name
- NCT06760845
- Testing
- Imaging Time
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Zunsong Wang
Systemic Lupus Erythematosus
Study of Systemic Lupus Erythematosus
This protocol will evaluate patients with systemic lupus erythematosus (SLE) and their relatives to learn more about how the disease develops and changes over time.
- Trial name
- NCT00001372
- Where
- United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Urinary Tract Infections in Children, Dexamethasone
Efficacy of Corticosteroids in Reducing Renal Scarring in Acute Pyelonephritis in Children
Urinary tract infection (UTI) is the most frequently occurring serious bacterial infection in young children and accounts 5 to 14% of emergency department visits Formation of renal scarring in children has been associated with…
- Conditions
- Urinary Tract Infections in Children, Dexamethasone, Kidney Scarring, Acute Pyelonephritis
- Trial name
- NCT04654507
- Testing
- Dexamethasone Oral
- Where
- Qatar
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Hamad Medical Corporation
Immunoglobulin A Nephropathy
A Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy.
This is a Phase I/II study designed to evaluate the safety, tolerability, PK and PD of subcutaneous MIL116, an anti-APRIL monoclonal antibody, in healthy participants and patients with IgA Nephropathy.
- Trial name
- NCT07375758
- Testing
- MIL116
- Where
- China
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Beijing Mabworks Biotech Co., Ltd.
Lupus Nephritis
Effect of Mesenchymal Stem Cell Transplantation for Lupus Nephritis
Mesenchymal Stem Cell (MSC) has been shown to have immunosuppressive and repairing properties. Manifestations of systemic lupus eryhematosus(SLE) may in most patients be ameliorated with medications that suppress the immune…
- Trial name
- NCT00659217
- Testing
- mesenchymal stem cell
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Organ Transplant Institute, China
Lupus Nephritis
Exploring Biomarkers for Therapeutic Response of Lupus Nephritis Based on Multi Omics Analysis
This is an observational study of patients with lupus nephritis aiming to find biomarkers that can predict patients' response to immunosuppressants.
- Trial name
- NCT06167174
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Chinese SLE Treatment And Research Group
Glomerulonephritis
Efficacy of Pentoxifylline on Rapidly Progressive Glomerulonephritis
We have recently demonstrated that pentoxifylline (PTX) has the potential to treat severe glomerular inflammation in a rat model of accelerated anti-glomerular basement membrane (GBM) glomerulonephritis.
- Trial name
- NCT00354198
- Testing
- pentoxifylline, corticosteroids
- Where
- Taiwan
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Idiopathic Membranous Nephropathy
Tacrolimus Treatment of Patients With Idiopathic Membranous Nephropathy
The purpose of this study is: To explore the potential role of tacrolimus in the treatment of membranous nephropathy. To investigate the safety and tolerability of tacrolimus vs methylprednisolone plus cyclophosphamide.
- Trial name
- NCT00302523
- Testing
- Tacrolimus
- Where
- 2 sites in China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Nanjing University School of Medicine
Autosomal Dominant Polycystic Kidney Disease (ADPKD), Advanced-Chronic Kidney Disease (CKD)
Establishment of the Human Intestinal and Salivary Microbiota Biobank - Kidney Diseases
This is a prospective, clinical, multicentre study aimed to collect biological samples and study microbiota from subjects suffering from chronic kidney disease and from healthy volunteers.
- Conditions
- Autosomal Dominant Polycystic Kidney Disease (ADPKD), Advanced-Chronic Kidney Disease (CKD), Diabetic Kidney Disease (DKD), IgA Nephropathy (IgAN)
- Trial name
- BIOMIS-Nefro (NCT04689074)
- Testing
- Biological sample collection, Questionnaire, Medical examination
- Where
- 2 sites in Italy
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
Healthy Subjects
Study to Evaluate the Pharmacokinetics of Oral Sparsentan Suspension
This single-center, open-label, randomized, single and multiple-dose, 3-way sequential study at 3 dose levels will be performed in healthy subjects. Subjects will be randomized to 1 of the 3 dose levels.
- Trial name
- NCT05562362
- Testing
- RE-021, sparsentan
- Where
- United Kingdom
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Travere Therapeutics, Inc.
Nephrotic Syndrome, Membranous Nephropathy
A Prospective Multi-dose Study of Apixaban in Subjects With Nephrotic Syndrome
This phase I study is a single arm, multi-dose study that will evaluate steady-state apixaban pharmacokinetics (PK) and pharmacodynamics (PD) in subjects with Nephrotic Syndrome (NS) vs healthy control subjects.
- Trial name
- NCT04278729
- Testing
- Apixaban 5 MG
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Focal Glomerulosclerosis
Tacrolimus Treatment of Patients With Idiopathic Focal Segmental Glomerulosclerosis
The purpose of this study is to assess the efficacy of Tacrolimus Treatment of patients with idiopathic focal segmental glomerulosclerosis.
- Trial name
- NCT00302536
- Testing
- Tacrolimus
- Where
- China
- Volunteers
- healthy volunteers welcome
- Sponsor
- Nanjing University School of Medicine
Lupus Nephritis, Lupus Erythematosus, Systemic
Establishing Clinical Utility of a New Diagnostic Test for Rheumatology Patients
This study will collect high-quality randomized controlled data from a nationally representative sample of practicing rheumatologists to determine how they currently manage patients with SLE (systemic lupus erythematosus) and how…
- Trial name
- NCT04266860
- Testing
- Experimental - Test Results and Education
- Where
- United States
- Volunteers
- 166 people, healthy volunteers welcome
- Sponsor
- Qure Healthcare, LLC
Glomerulonephritis
Study of HRS-5965 in Healthy Subjects and Subjects With Renal Insufficiency
The trial is the first human trial. The safety, tolerability, PK and PD of HRS-5965 tablets will be evaluated in healthy subjects and subjects with impaired renal function.
- Trial name
- NCT05505955
- Testing
- HRS-5965
- Where
- China
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Chengdu Suncadia Medicine Co., Ltd.
IgA Nephropathy (IgAN)
IBI3034 Study in Healthy Adults and Patients With Primary IgA Nephropathy
Part 1 is a Single Ascending Dose (SAD) study, and Part 2 is a Multiple Ascending Dose (MAD) study
- Trial name
- NCT07886476
- Testing
- IBI3034, Telitacicept
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Lupus Nephritis
TF, TFPI and Plasmin as Novel Bio-markers in Early Diagnosis of Lupus Nephritis
Urinary levels of plasmin ,TF , and TFPI are all elevated in active LN patients compared to inactive LN patients and healthy controls. All four proteins correlated with systemic disease activity and renal disease activity.
- Trial name
- NCT04218890
- Testing
- Urinary tissue factor (TF), tissue factor pathway inhibitor (TFPI) and plasmin
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Assiut University
IgA Nephropathy, Focal Segmental Glomerulosclerosis
A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects
The purpose of this first in human study is to evaluate the safety, tolerability, pharmacokinetics (PK),and pharmacodynamics (PD) of HS-10390 in healthy subjects.
- Trial name
- NCT05942625
- Testing
- HS-10390 tablet
- Where
- China
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Hansoh BioMedical R&D Company
Focal Segmental Glomerulosclerosis, Nephrotic Syndrome
Genetic Causes of FSGS, Nephrotic Syndrome, or Kidney Failure
The investigators are trying to learn more about the cause of kidney diseases such as Focal Segmental Glomerulosclerosis (FSGS) and Nephrotic syndrome by studying genetics.
- Conditions
- Focal Segmental Glomerulosclerosis, Nephrotic Syndrome, End Stage Renal Disease, Kidney Failure
- Trial name
- FSGS (NCT02194582)
- Where
- United States
- Volunteers
- 2,050 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Autoimmune Membranous Nephropathy
Peptide GAM Immunoadsorption Therapy in Autoimmune Membranous Nephropathy
Autoimmune Membranous Nephropathy is now understood to be a condition caused by the immune system although the exact mechanism is not completely known.
- Trial name
- PRISM (NCT03255447)
- Testing
- Immunoadsorption
- Where
- 3 sites in United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Manchester University NHS Foundation Trust
IgA Nephropathy
IgA Nephropathy, Lymphocyte Homing and IgA Class Switch
IgA nephropathy (IgAN) is the most common primary glomerulonephritis in the world and it represents an important cause of end-stage kidney failure.
- Trial name
- NIDOCIGA (NCT01775527)
- Testing
- blood test
- Where
- France
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- University Hospital, Limoges